Thomas H Inge1, Ronald L Prigeon2, Deborah A Elder3, Todd M Jenkins3, Robert M Cohen4, Stavra A Xanthakos3, Stephen C Benoit4, Lawrence M Dolan3, Stephen R Daniels5, David A D'Alessio6. 1. Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Electronic address: thomas.inge@cchmc.org. 2. University of Maryland School of Medicine, and Baltimore VA Medical Center Geriatric Research, Education and Clinical Center, Baltimore, MD. 3. Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 4. Department of Psychiatry, University of Cincinnati, Cincinnati, OH. 5. University of Colorado School of Medicine, Denver, CO. 6. Division of Endocrinology, Diabetes and Metabolism, Duke University Medical Center, Durham, NC; Durham Veteran's Affairs Medical Center, Durham, NC.
Abstract
OBJECTIVE: To test the hypothesis that insulin secretion and insulin sensitivity would be improved in adolescents after Roux-en-Y gastric bypass (RYGB). STUDY DESIGN: A longitudinal study of 22 adolescents and young adults without diabetes undergoing laparoscopic RYGB (mean age 17.1 ± 1.42 years; range 14.5-20.1; male/female 8/14; Non-Hispanic White/African American 17/5) was conducted. Intravenous glucose tolerance tests were done to obtain insulin sensitivity (insulin sensitivity index), insulin secretion (acute insulin response to glucose ), and the disposition index as primary outcome variables. These variables were compared over the 1 year of observation using linear mixed modeling. RESULTS: In the 1-year following surgery, body mass index fell by 38% from a mean of 61 ± 12.3 to 39 ± 8.0 kg/m(2) (P < .01). Over the year following surgery, fasting glucose and insulin values declined by 54% and 63%, respectively. Insulin sensitivity index increased 300% (P < .01), acute insulin response to glucose decreased 56% (P < .01), leading to a nearly 2-fold increase in the disposition index (P < .01). Consistent with improved β-cell function, the proinsulin to C-peptide ratio decreased by 21% (P < .01). CONCLUSIONS: RYGB reduced body mass index and improved both insulin sensitivity and β-cell function in severely obese teens and young adults. These findings demonstrate that RYGB is associated with marked metabolic improvements in obese young people even as significant obesity persists. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00360373.
OBJECTIVE: To test the hypothesis that insulin secretion and insulin sensitivity would be improved in adolescents after Roux-en-Y gastric bypass (RYGB). STUDY DESIGN: A longitudinal study of 22 adolescents and young adults without diabetes undergoing laparoscopic RYGB (mean age 17.1 ± 1.42 years; range 14.5-20.1; male/female 8/14; Non-Hispanic White/African American 17/5) was conducted. Intravenous glucose tolerance tests were done to obtain insulin sensitivity (insulin sensitivity index), insulin secretion (acute insulin response to glucose ), and the disposition index as primary outcome variables. These variables were compared over the 1 year of observation using linear mixed modeling. RESULTS: In the 1-year following surgery, body mass index fell by 38% from a mean of 61 ± 12.3 to 39 ± 8.0 kg/m(2) (P < .01). Over the year following surgery, fasting glucose and insulin values declined by 54% and 63%, respectively. Insulin sensitivity index increased 300% (P < .01), acute insulin response to glucose decreased 56% (P < .01), leading to a nearly 2-fold increase in the disposition index (P < .01). Consistent with improved β-cell function, the proinsulin to C-peptide ratio decreased by 21% (P < .01). CONCLUSIONS: RYGB reduced body mass index and improved both insulin sensitivity and β-cell function in severely obese teens and young adults. These findings demonstrate that RYGB is associated with marked metabolic improvements in obese young people even as significant obesity persists. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00360373.
Authors: N B Jørgensen; S H Jacobsen; C Dirksen; K N Bojsen-Møller; L Naver; L Hvolris; T R Clausen; B S Wulff; D Worm; D Lindqvist Hansen; S Madsbad; J J Holst Journal: Am J Physiol Endocrinol Metab Date: 2012-04-24 Impact factor: 4.310
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Melissa A Reed; Walter J Pories; William Chapman; John Pender; Rita Bowden; Hisham Barakat; Timothy P Gavin; Tom Green; Ed Tapscott; Donghai Zheng; Nigel Shankley; Lynn Yieh; David Polidori; Steven P Piccoli; Leona Brenner-Gati; G Lynis Dohm Journal: J Clin Endocrinol Metab Date: 2011-05-18 Impact factor: 5.958
Authors: Mary Savoye; Paulina Nowicka; Melissa Shaw; Sunkyung Yu; James Dziura; Georgia Chavent; Grace O'Malley; John B Serrecchia; William V Tamborlane; Sonia Caprio Journal: Pediatrics Date: 2011-02-07 Impact factor: 7.124
Authors: Petter Bjornstad; Kara Hughan; Megan M Kelsey; Amy S Shah; Jane Lynch; Edward Nehus; Mark Mitsnefes; Todd Jenkins; Peixin Xu; Changchun Xie; Thomas Inge; Kristen Nadeau Journal: Diabetes Care Date: 2019-11-04 Impact factor: 19.112
Authors: Claudia K Fox; Amy C Gross; Eric M Bomberg; Justin R Ryder; Megan M Oberle; Carolyn T Bramante; Aaron S Kelly Journal: Curr Obes Rep Date: 2019-09
Authors: J R Ryder; A C Gross; C K Fox; A M Kaizer; K D Rudser; T M Jenkins; M B Ratcliff; A S Kelly; S Kirk; R M Siegel; T H Inge Journal: Int J Obes (Lond) Date: 2017-08-14 Impact factor: 5.095
Authors: Emily K Sims; Zunaira Chaudhry; Renecia Watkins; Farooq Syed; Janice Blum; Fangqian Ouyang; Susan M Perkins; Raghavendra G Mirmira; Jay Sosenko; Linda A DiMeglio; Carmella Evans-Molina Journal: Diabetes Care Date: 2016-07-06 Impact factor: 19.112